AJ Lanigan: Yes. In Fact, pharma corporations are building major dollars with solutions like Keytruda and Opdivo that deal with PD-one and PD-L1. Below’s the super interesting part: think about checkpoints as site visitors indicators. You don’t want an immune process that’s operating wild like a freight educate above a waiting for link from Social Bookmarking (4)